Johannesburg, South Africa — Despite accounting for about a quarter of the global disease burden, Africa remains largely invisible in clinical trials.
A study examining the landscape of global medical research reveals a profound imbalance, with African populations underrepresented in trials that are fundamental to evidence — based medicine.
The study, led by physician — scientist Bamba Gaye, reveals that only 3. 9% of trials across the five most prestigious general medical journals were conducted exclusively in Africa.
In cardiovascular health, the numbers are even more startling, with just 0. 6% of trials conducted solely on the continent. This absence of African representation raises serious concerns about the external validity of clinical trial results.
When trials exclude African populations, the findings lack the generalizability necessary to ensure that treatments are safe and effective for all patients.
The gap is further compounded by the focus of most Africa — based trials on infectious diseases, despite the rising burden of non-communicable diseases like cardiovascular disease, diabetes, and hypertension. This misalignment in research priorities is especially problematic as the African middle class has grown exponentially, leading to increased life expectancy and a subsequent rise in chronic diseases.
The study also points to the existence of disparities in treatment safety profiles between populations, such as the higher risk of severe side effects in African patients from certain blood pressure medications. This underscores the importance of including African populations in clinical trials to ensure that medical treatments are tailored to the continent’s diverse population. Addressing the gap in clinical research is not just a matter of health equity; it is also critical for global health security.
As the world grapples with the dual challenges of infectious diseases and non — communicable diseases, Africa’s inclusion in clinical trials is essential for developing treatments that are effective, safe, and appropriate for all populations.
The African Union’s Agenda 2063 and other global initiatives must be leveraged to foster indigenous research capabilities in Africa and ensure the continent’s voice is heard in the corridors of global health research.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: Bamba Gaye
